CD274 and non-small cell lung carcinoma: Single-agent pembrolizumab has been the benchmark standard as initial treatment for metastatic NSCLC with PD-L1 expression ≥50% as a result of evidence, including from the seminal KEYNOTE-024 trial, demonstrating greater overall survival and progression-free survival with pembrolizumab compared with platinum-based chemotherapy [9].